Treatment with octreotide to suppress corticotropin secretion by a carcinoid tumour.
作者信息
Tirovola Eugenia B, Malpas James S
机构信息
First Department of Internal Medicine and Nosology, University of Athens Medical School, Athens, Greece.
出版信息
J R Soc Med. 2005 Nov;98(11):516. doi: 10.1177/014107680509801116.
Abstract
摘要
相似文献
1
Treatment with octreotide to suppress corticotropin secretion by a carcinoid tumour.用奥曲肽治疗以抑制类癌肿瘤分泌促肾上腺皮质激素。
J R Soc Med. 2005 Nov;98(11):516. doi: 10.1177/014107680509801116.
2
Carcinoid of the pancreas.胰腺类癌
Pancreatology. 2002;2(2):163-6. doi: 10.1159/000055907.
3
Use of somatostatin analog for localization and treatment of ACTH secreting bronchial carcinoid tumor.生长抑素类似物在促肾上腺皮质激素分泌型支气管类癌肿瘤定位及治疗中的应用。
Chest. 1996 Mar;109(3):845-6. doi: 10.1378/chest.109.3.845.
4
Octreotide LAR in carcinoid: how to dose?长效奥曲肽用于类癌：如何给药？
Pancreas. 2008 Oct;37(3):337-8; author reply 338-9. doi: 10.1097/MPA.0b013e31818adf4b.
5
Comments on "Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients".关于“类癌患者长效奥曲肽重复治疗期间监测血浆奥曲肽水平的临床价值”的评论
Pancreas. 2008 Oct;37(3):334-5; author reply 336-7. doi: 10.1097/MPA.0b013e31818adf6e.
6
Octreotide therapy in carcinoid disease.
Anticancer Drugs. 1996 Jan;7 Suppl 1:17-22. doi: 10.1097/00001813-199601001-00004.
7
Nasopharyngeal carcinoid tumor: successful therapy for a tumor in a unique location.鼻咽类癌肿瘤：对一个位于独特部位的肿瘤的成功治疗
Otolaryngol Head Neck Surg. 2009 Mar;140(3):437-8. doi: 10.1016/j.otohns.2008.11.007.
8
[Octreotide + bilateral adrenalectomy in the management of ACTH-producing carcinoid tumors].[奥曲肽联合双侧肾上腺切除术治疗促肾上腺皮质激素分泌型类癌肿瘤]
Arq Bras Endocrinol Metabol. 2005 Oct;49(5):791-6. doi: 10.1590/s0004-27302005000500020. Epub 2006 Jan 23.
9
Intractable hypercalcemia due to a metastatic carcinoid secreting parathyroid hormone-related peptide and interleukin-6: response to octreotide.因转移性类癌分泌甲状旁腺激素相关肽和白细胞介素-6导致的难治性高钙血症：对奥曲肽的反应
Am J Med Sci. 1999 Sep;318(3):203-5. doi: 10.1097/00000441-199909000-00019.
10
The tumour vanishes.
Clin Endocrinol (Oxf). 2000 Dec;53(6):663-4. doi: 10.1046/j.1365-2265.2000.01109.x.
本文引用的文献
1
Somatostatin receptors in pituitary function, diagnosis and therapy.生长抑素受体在垂体功能、诊断及治疗中的作用
Front Horm Res. 2004;32:235-52. doi: 10.1159/000079048.
2
Octreotide exerts different effects in vivo and in vitro in Cushing's disease.奥曲肽在库欣病中体内和体外发挥不同作用。
Eur J Endocrinol. 1994 Feb;130(2):125-31. doi: 10.1530/eje.0.1300125.
3
Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors.垂体瘤中两种生长抑素受体亚型的异质性表达。
J Clin Endocrinol Metab. 1994 Feb;78(2):398-403. doi: 10.1210/jcem.78.2.8106629.
4
Point mutation of the somatostatin receptor 2 gene in the human small cell lung cancer cell line COR-L103.
Biochem Biophys Res Commun. 1995 May 25;210(3):805-15. doi: 10.1006/bbrc.1995.1730.
5
Failure of somatostatin analogue SMS 201-995 to control Cushing's syndrome due to ectopic release of ACTH from a bronchial carcinoid.生长抑素类似物SMS 201-995无法控制因支气管类癌异位分泌促肾上腺皮质激素（ACTH）所致的库欣综合征。
Scott Med J. 1989 Oct;34(5):533-4. doi: 10.1177/003693308903400510.
Zotero 插件